New developments with vancomycin-resistant enterococci: E. faecium-friend or foe?

Journal of Infectious Diseases

Volumn 200, Issue 5, 2009, Pages 679-681

  Bertics, Paul J ^a,b   Wiepz, Gregory J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL PERITONITIS; BACTERIAL STRAIN; CRITICALLY ILL PATIENT; DISEASE TRANSMISSION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HOSPITAL INFECTION; HUMAN; INFLAMMATION; MACROPHAGE; NEUTROPHIL; NONHUMAN; NOTE; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; CANADA; DRUG EFFECT; GRAM POSITIVE INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; UNITED STATES;

ANTI-BACTERIAL AGENTS; CANADA; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 70349304211     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605477     Document Type: Note

References (22)

1. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-118
2. 2. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycinresistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008; 41: 385-392 (Pubitemid 351330734)
3. 3. Uttley AH, George RC, Naidoo J, et al. Highlevel vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989; 103:173-181 (Pubitemid 19223468)
4. 4. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005; 18:300-305 (Pubitemid 41017633)
5. Leavis HL, Bonten MJ, Willems RJ. Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr Opin Microbiol 2006; 9:454-460
6. Willems RJ, Bonten MJ. Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007;20:384-390
7. Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008; 9:567-571
8. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007;28:632-645
9. Warren DK, Nitin A, Hill Q Fraser VJ, Kollef MH. Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004;25:99-104.
10. 10. Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53:307-310 (Pubitemid 41796903)
11. Boyce JM, Cookson B, Christiansen K, et al. Methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2005; 5:653-663
12. Courvalin P. Vancomycin resistance in grampositive cocci. Clin Infect Dis 2006;42(Suppl l):S25-34.
13. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007;51:231-238
14. Maor Y, Hagin M, Belausov N, Keller N, BenDavid D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199:619-624
15. Leenderste M, Willems RJL, Oei GA, Florquin S, Bonten MJM, van der Poll T. Intestinal Enterococcus faecium colonization improves host defense during polymicrobial peritonitis. J Infect Dis 2009;200:735-744 (in this issue).
16. Montravers P, Mohler J, Saint Julien L, Carbon C. Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Infect Immun 1997;65:144-149
17. Leendertse M, Willems RJ, Giebelen IA, Roelofs JJ, Bonten MJ, van der Poll T. Neutrophils are essential for rapid clearance of Enterococcus faecium in mice. Infect Immun 2009; 77: 485-491
18. Leendertse M, Willems RJ, Giebelen IA, et al. Cecal ligation and puncture induced sepsis impairs host defense against Enterococcus faecium peritonitis. Intensive Care Med 2009; 35: 924-932
19. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr 2001; 73:444S-50S.
20. Boirivant M, Strober W The mechanism of action of probiotics. Curr Opin Gastroenterol 2007;23:679-692
21. Sabia Q de Niederhausem S, Guerrieri E, et al. Detection of bacteriocin production and virulence traits in vancomycin-resistant enterococci of different sources. J Appl Microbiol 2008; 104:970-979
22. Svetoch EA, Eruslanov BV, Perelygin W, et al. Diverse antimicrobial killing by Enterococcus faecium E 50-52 bacteriocin. J Agric Food Chem 2008;56:1942-1948